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| INTRODUC TI ON
With an influx of treatments recently approved or in late-stage clinical development, the haemophilia A landscape is evolving.
1 These therapies not only have the potential to improve health outcomes (eg reduced bleeds), but also offer improvements in mode of administration (eg subcutaneous injection, oral) and required frequency of administration (eg once a week or month). The emergence of therapies with modified value propositions might provide people with haemophilia A (PWHA) with additional treatment options that could influence how they experience the treatment itself.
Indeed, given that haemophilia A is a chronic disease that currently requires frequent intravenous infusions, experiences with current treatments may be as important as the health outcomes conferred by individual therapies. Studies have shown that PWHA and caregivers experience challenges with current treatments (eg financial, technical, educational) 2-5 that can impact their quality of life (QoL; eg physical functioning, psychosocial health). 6 In turn, these impacts may affect adherence to prescribed treatment, leaving PWHA at an increased risk of bleeding and joint damage. 7 Given the broader innovations that new therapies are bringing to haemophilia treatment and their potential to address recognized challenges and impacts with current treatments, it will be important to build a deeper understanding of PWHA and caregiver experiences with existing options. This understanding will help characterize and prioritize the potential value of emerging therapies.
Previous studies exploring treatment-related challenges have primarily collected survey data 6, 8, 9 or focused on sub-sets of the PWHA population. 4 While these studies provide valuable information, survey-based approaches do not capture candid perspectives or allow for follow-up questions. By engaging in direct conversations with PWHA and caregivers, this study's objective was to complement existing literature with firsthand insights on experiences with current treatments and uncover associations between treatment-related challenges, impacts on QoL and desired improvements in future therapies.
| ME THODS

| Approach
Our approach was modelled on a modified Delphi method to zero in on areas of consensus after successive rounds of participant engagement. The first stage involved one-on-one interviews using structured questionnaires to uncover challenges with current treatments, the impact of challenges on QoL and desired improvements in new therapies. The second stage re-engaged participants in focus groups to present, validate and further characterize and prioritize findings from interviews. All participants were compensated for their time.
| Setting
Sixty-minute teleconference interviews were conducted by two researchers-one leading the interview and the other taking notes.
Audio recordings were taken to revisit key points for further clarification; participant consent was received prior to initiating the interview. Two-hour teleconference focus groups with the initial cohort (divided into two groups to maintain a manageable number) were conducted after the completion of the one-on-one interviews. Two researchers were involved and audio recordings were taken (with consent).
| Sampling method
We worked closely with national and regional representatives from the Canadian Hemophilia Society (CHS) and healthcare professionals from institutions providing haemophilia care to gather input on ideal characteristics for our cohort of participants (Table 1) . Specifically, we sought to speak with both PWHA directly (>18 years of age) as well as caregivers of PWHA (to gather insights from the caregiver perspective and on behalf of PWHA <18 years of age). The target population was non-inhibitor PWHA, specifically individuals with more severe clinical manifestations of the disease and, subsequently, a greater need for treatment. Other characteristics were identified to reflect the diversity of the Canadian PWHA population, including the following: age, provincial distribution and urban/rural setting (based on the distance to the nearest haemophilia treatment centre [HTC] ). Based on these ideal characteristics, regional CHS representatives engaged with prospective participants and received consent from 28 individuals to be included in the selection process for the study. A final cohort of 20 PWHA and caregivers of PWHA was selected to align with our ideal breakdown (Table 1) ; these individuals were engaged to re-confirm participation in the study and initiate interviews.
| Data collection and analysis
Interview guides were developed for both PWHA and caregivers. 
| RE SULTS
| Participants
Of the 20 participants selected for this study, 12 were PWHA and 8 were caregivers (either the mother or father of children or pre-teens/teens who are <18 years of age). Initial one-on-one consultations with PWHA or caregivers confirmed that the individuals with haemophilia who were receiving treatment did not have inhibitors at the time of the study. The majority of PWHA (16 in total; including all severe and one moderate PWHA) were receiving prophylactic treatment; the remainder were receiving on-demand treatment. Our cohort ranged in age from 2.5 to 84 years, and the distribution across disease severity and province was representative of the distribution of PWHA across Canada (see Table 1 for a comparison of ideal and actual cohort characteristics). All 20 participants (PWHA and caregivers) were involved in the one-on-one interviews. Sixteen individuals participated in focus groups, while four were unable to attend due to scheduling conflicts. The demographic characteristics for each participant (ie the PWHA-whether engaged directly or indirectly through caregiver discussions) can be found in Table 2 .
| Challenges with current treatment
Key findings across challenges, impacts on Q oL and desired improvements for future therapies are summarized in 85% Urban 15% Rural a Caregivers were interviewed to gather their own firsthand perspectives and reflect insights on behalf of their children (ie <18 y of age). b Disease Severity: Mild (5%-40% factor VIII activity); Moderate (1%-5% factor VIII activity); Severe (<1% factor VIII activity).
TA B L E 1 Ideal and actual cohort characteristics
with treatment administration and coordinating schedules were most problematic.
| Administering an intravenous infusion
Caregivers identified the time commitment required for treatment as the most significant issue with current treatments. Complications associated with intravenous infusions (eg inability to find a vein or self-administer due to injury) can cause additional inconveniences by extending the administration protocol or necessitating visits to an HTC. For individuals with moderate/severe haemophilia who require frequent infusions, it can be challenging to find a viable vein due to the formation of scar tissue. Interstitial IV is another major challenge inherent to infusions. Further, most PWHA and caregivers noted the steep learning curve associated with infusions, requiring considerable time investment and multiple visits to HTCs to acquire the necessary skills.
Many caregivers mentioned that infusing a child presents unique challenges, including helping the child overcome a fear of needles, alleviating the perception that the caregiver (often a parent) is hurting the child, and psychologically and physically preparing the child for their regular infusions. Most caregivers find it challenging to infuse children through a port, given the precision required and potential blockages. Health concerns were also raised by most caregivers around the use of a port, including an increased risk of infection, the need for adjunctive treatment and follow-on surgeries.
Most caregivers also noted that the transition from injections using a port to peripheral infusions offers additional challenges such as becoming familiar with a new administration protocol.
Some PWHA and caregivers mentioned that intravenous infusions can be painful, especially when multiple attempts are required.
One individual with severe haemophilia noted that he intentionally foregoes treatment if he is at a lower risk of injury (eg when staying at home) because of the pain the infusion causes.
| Coordinating treatment schedules
All participants noted that it is challenging early on to establish and maintain a consistent treatment schedule, leading to 
| Impact of current treatment on QoL
While impacts across multiple dimensions of QoL were identified, the majority of PWHA and caregivers stated that treatment-related challenges have the greatest impact on their psychosocial well-being.
| Psychological well-being
Both PWHA and caregivers expressed a worry about whether their current treatment will result in the development of inhibitors.
Additionally, most caregivers noted the anguish they feel in seeing their child experience stress (eg from a fear of needles) and pain during the infusion. Most caregivers indicated that the relationship with their child is temporarily affected during the infusion process due to the pain the child experiences, while a few caregivers highlighted negative associations their child has with hospitals and/or healthcare professionals given the intravenous infusions.
| Physical impact
Individuals with severe haemophilia noted substantial vein damage due to frequent infusions, including permanent scar tissue/ bruises. Most caregivers stated that they are often physically exhausted by attempting to infuse a child that is not sitting still or fighting back.
| Impact on personal/social life
A few caregivers noted that it can be difficult to find time to spend with significant others due to treatment (and disease-related) challenges or finding a partner who understands the disease and is willing to assist with treatment. Some young adults with severe haemophilia mentioned their general reluctance to infuse in public due to infusion (and disease-related) stigma. A similar social stigma has been observed by caregivers when their child is taken aside to receive an infusion (eg at school).
| Work-related issues
All caregivers and some PWHA mentioned the need to take time off work for treatment, and the impact on productivity and co-worker perceptions. A few caregivers noted that the need to manage their child's treatment hinders their employment options, as they need sufficient flexibility (and understanding) to accommodate the treatment schedule. In certain cases, caregivers had to switch to a job that could be performed from home to better manage their child's treatment schedules.
| Desired improvements for future therapies
Most PWHA and caregivers recognized the impact that a disease- 
| D ISCUSS I ON AND CON CLUS I ON
This study offers firsthand perspectives from PWHA and caregivers across Canada on treatment outcomes and impacts that matter most to them, supporting findings from previous studies 
| Psychosocial well-being
The impact of haemophilia on psychosocial well-being is well-known.
Studies have shown that one-third of PWHA have depression symptoms, 10,11 while other psychosocial outcomes (eg self-esteem/ self-autonomy) are also negatively impacted. 12 Our study shows that the nature of haemophilia treatment can compound the psychosocial impact of the disease. Many individuals worry about the development of inhibitors with current treatments-which occurs in 33% of individuals with severe haemophilia A and requires a shift in prescribed medication. 13 Other treatment impacts-from constant infusions to physical scars to personal/professional relationships-were also recognized as negatively affecting psychosocial well-being.
Poorer mental/social well-being can pose economic challenges through reduced production and consumption opportunities, as well as increased health and social care expenditures.
14 Recognizing the broad impact of treatment-related challenges on psychosocial wellbeing and implications on health systems and economic prosperity, the study reinforces the importance of psychosocial support to help mitigate these issues.
| Employment
The study offers support for an impact of treatment schedules on the ability to attain desired employment. Individuals often feel limited in their job choice and ability to attain professional goals due to treatment-related challenges, noting that treatment protocols impact productivity and influence co-worker perceptions. In certain 
| Adherence to prescribed treatment regimens
Our study affirms that the complexity of current treatment protocols compels individuals to make tough decisions around treatment adherence. PWHA and caregivers acknowledge many challenges that lead to intermittent delays in administration or missed infusions, including difficulty finding a vein, physical impediments and unexpected changes in schedules. It is well documented that adherence to prophylaxis is essential for maintaining circulating factor levels above established targets and critical to better health outcomes (eg preventing bleeds and arthropathy). [16] [17] [18] A longitudinal study examining adherence to early prophylactic therapy in 49 PWHA reported that 69% of patients interrupted prophylactic treatment one or more times during the study and had significantly more arthropathy. 17 Other studies have shown that increasing the time between treatments is associated with a greater number of total bleeds and hemarthroses, and lowered adherence is the most important determinant of increased bleeding. 19 There is also a substantial cost to the health system associated with bleeding episodes-ranging from €6650 to €14 138 per bleed (data from Germany, Sweden, the United Kingdom and the Netherlands). 20 While not examined in this study, it is reasonable to conclude that lower adherence in this study's cohort could result in an increased risk of bleeds and have a negative impact on PWHA and caregiver QoL.
Several limitations must be considered in interpreting the results of this study. This study focused on non-inhibitor PWHA only and cannot be generalized to haemophilia B or inhibitor populations.
Further, the study focused on gathering perspectives from PWHA and caregivers across Canada; it is possible perspectives from in- 
